A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages -
Publisher
Informa UK Limited
Online
2023-10-29
DOI
10.1080/14740338.2023.2277801
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data
- (2022) Chunyan Wei et al. International Journal of Clinical Pharmacy
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
- (2022) Sara A Hurvitz et al. LANCET
- Pharmacovigilance‐based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections
- (2021) Ruwen Böhm et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Risk Minimization of Antibody–Drug Conjugates in Oncology: A Review
- (2021) Fabio A. Lievano et al. DRUG SAFETY
- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
- (2021) Paolo F Caimi et al. LANCET ONCOLOGY
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
- (2021) Salvatore Siena et al. LANCET ONCOLOGY
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
- (2021) Evan Y Yu et al. LANCET ONCOLOGY
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
- (2021) Sara M. Tolaney et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia
- (2020) Eunice S. Wang et al. LEUKEMIA & LYMPHOMA
- FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
- (2020) Elaine Chang et al. CLINICAL CANCER RESEARCH
- Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis
- (2020) S. Greten et al. JOURNAL OF NEURAL TRANSMISSION
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
- (2019) Hagop M. Kantarjian et al. CANCER
- Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
- (2019) Prathap Kumar Mahalingaiah et al. PHARMACOLOGY & THERAPEUTICS
- Polatuzumab Vedotin: First Global Approval
- (2019) Emma D. Deeks DRUGS
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
- (2019) C. Kimberly Tsui et al. Nature Chemical Biology
- An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates
- (2019) Haleh Saber et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting
- (2018) Auayporn Nademanee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
- (2018) Robert J. Kreitman et al. LEUKEMIA
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial
- (2018) Juliette Lambert et al. HAEMATOLOGICA
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists
- (2018) Lars Mecklenburg TOXICOLOGIC PATHOLOGY
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
- (2017) Joanna C. Masters et al. INVESTIGATIONAL NEW DRUGS
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- (2017) H Miles Prince et al. LANCET
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- A curated and standardized adverse drug event resource to accelerate drug safety research
- (2016) Juan M. Banda et al. Scientific Data
- Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma
- (2015) Robert Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™
- (2015) Ayako Suzuki et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives
- (2014) Robert J. Fontana GASTROENTEROLOGY
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Profiling Cumulative Proportional Reporting Ratios of Drug-Induced Liver Injury in the FDA Adverse Event Reporting System (FAERS) Database
- (2013) Allen D. Brinker et al. DRUG SAFETY
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- LiverTox: A website on drug-induced liver injury
- (2012) Jay H. Hoofnagle et al. HEPATOLOGY
- Acute Liver Failure Due to Drugs
- (2008) Robert Fontana SEMINARS IN LIVER DISEASE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started